- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07192471
- Procès original
Une première étude humaine de KK2223 chez les participants atteints de lymphome non hodgkinien en rechute ou réfractaire
Une phase 1, multicentrique, en ouvert, non randomisée, à l'escalade de dose et à un remblai de KK2223 chez les participants avec un lymphome non hodgkinaire à cellules T rechutée ou réfractaire
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kyowa Kirin, Inc.
- Numéro de téléphone: +1-609-919-1100
- E-mail: KKD.Clinical.82@kyowakirin.com
Lieux d'étude
-
-
-
Madrid, Espagne, 28027
- Pas encore de recrutement
- Clinica Universidad de Navarra - Hematología y Hemoterapia
-
Contact:
- Miguel Canales Albendea
- Numéro de téléphone: 34917277116
- E-mail: macanales@unav.es
-
Chercheur principal:
- Migue Canales Albendea
-
-
Barcelona
-
Badalona, Barcelona, Espagne, 8036
- Pas encore de recrutement
- Hospital Clinic De Barcelona - Hematología
-
Chercheur principal:
- Pablo Mozas
-
Contact:
- Pablo Mozas
- Numéro de téléphone: 34 93 227 22 71
- E-mail: mozas@clinic.cat
-
L'Hospitalet de Llobregat, Barcelona, Espagne, 8907
- Pas encore de recrutement
- Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
-
Chercheur principal:
- Eva Domingo Domenech
-
Contact:
- Eva Domingo Domenech
- Numéro de téléphone: 34932607822
- E-mail: edomingo@iconcologia.net
-
-
Navarre
-
Pamplona, Navarre, Espagne, 31008
- Pas encore de recrutement
- Clinica Universidad de Navarra - Hematología
-
Contact:
- Miguel Canales Albendea
- Numéro de téléphone: 34917277116
- E-mail: macanales@unav.es
-
Chercheur principal:
- Miguel Canales Albendea
-
-
-
-
-
Bergamo, Italie, 24127
- Pas encore de recrutement
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
-
Chercheur principal:
- Giuseppe Gritti
-
Contact:
- Giuseppe Gritti
- Numéro de téléphone: 39035269492
- E-mail: giuseppe_gritti@yahoo.it
-
Bologna, Italie, 40138
- Pas encore de recrutement
- Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
-
Contact:
- Luigi Zinzani Pier
- Numéro de téléphone: 390516363680
- E-mail: pierluigi.zinzani@unibo.it
-
Chercheur principal:
- Luigi Zinzani Pier
-
Torino, Italie, 10126
- Pas encore de recrutement
- AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
-
Contact:
- Federica Cavallo
- Numéro de téléphone: 390116334264
- E-mail: f.cavallo@unito.it
-
Chercheur principal:
- Federica Cavallo
-
-
Torino
-
Candiolo, Torino, Italie, 10060
- Pas encore de recrutement
- Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
-
Chercheur principal:
- Umberto Vitolo
-
Contact:
- Umberto Vitolo
- Numéro de téléphone: 390116335934
- E-mail: umberto.vitolo@ircc.it
-
-
-
-
California
-
Duarte, California, États-Unis, 91010
- Pas encore de recrutement
- City of Hope
-
Chercheur principal:
- Christina Poh
-
Contact:
- Christina Poh
- Numéro de téléphone: 916-734-7131
- E-mail: cpoh@coh.org
-
Orange, California, États-Unis, 92868
- Pas encore de recrutement
- University of California, Irvine Medical Center - Hematology/Oncology
-
Contact:
- Lauren Pinter Brown
- Numéro de téléphone: 7144568200
- E-mail: lpinterb@uci.edu
-
Chercheur principal:
- Lauren Pinter Brown
-
Stanford, California, États-Unis, 94305
- Recrutement
- Stanford University School of Medicine
-
Chercheur principal:
- Youn Kim
-
Contact:
- Youn Kim
- Numéro de téléphone: 650-723-7893
- E-mail: younkim@stanford.edu
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- Pas encore de recrutement
- Moffit Cancer Center
-
Contact:
- Yumeng Zhang
- Numéro de téléphone: 844-304-8636
- E-mail: yumeng.zhang@moffitt.org
-
Chercheur principal:
- Yumeng Zhang
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Pas encore de recrutement
- Emory University Medical Center
-
Chercheur principal:
- Pamela Allen
-
Contact:
- Pamela Allen
- Numéro de téléphone: 404-778-2407
- E-mail: pallen5@emory.edu
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Pas encore de recrutement
- University of Iowa Health
-
Chercheur principal:
- Eric Mou
-
Contact:
- Eric Mou
- Numéro de téléphone: 800-777-8442
- E-mail: eric-mou@uiowa.edu
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Pas encore de recrutement
- Beth Israel Deaconess Medical Center - Research
-
Contact:
- Salvia Jain
- Numéro de téléphone: 617-726-2000
- E-mail: salvia.jain@mgh.harvard.edu
-
Chercheur principal:
- Salvia Jain
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Recrutement
- Washington University School of Medicine - Oncology Hospital - Public
-
Chercheur principal:
- Neha Mehta Shah
-
Contact:
- Neha Mehta Shah
- Numéro de téléphone: 314.273-8566
- E-mail: mehta-n@wustl.edu
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601-2105
- Pas encore de recrutement
- Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
-
Chercheur principal:
- Tatyana Feldman
-
Contact:
- Tatyana Feldman
- Numéro de téléphone: 551-996-5900
- E-mail: tatyana.feldman@hmhn.org
-
-
New York
-
New York, New York, États-Unis, 10021-6007
- Recrutement
- Memorial Sloan Kettering Cancer Center
-
Chercheur principal:
- Jasmine Zain
-
Contact:
- Jasmine Zain
- Numéro de téléphone: 212-639-3045
- E-mail: zainj1@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Pas encore de recrutement
- University Hospitals Cleveland Medical Center
-
Contact:
- Kevin Cooper
- Numéro de téléphone: 216-844-8200
- E-mail: kevin.cooper@uhhospitals.org
-
Chercheur principal:
- Kevin Cooper
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Pas encore de recrutement
- Oregon Health & Science University
-
Contact:
- Craig Okada
- Numéro de téléphone: 503-494-8397
- E-mail: okadac@ohsu.edu
-
Chercheur principal:
- Craig Okada
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Pas encore de recrutement
- University of Pennsylvania - Abramson Cancer Center
-
Chercheur principal:
- Stefan Barta
-
Contact:
- Stefan Barta
- Numéro de téléphone: 215-728-2674
- E-mail: Stefan.Barta@pennmedicine.upenn.edu
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas - MD Anderson Cancer Center
-
Chercheur principal:
- Ranjit Nair
-
Contact:
- Ranjit Nair
- Numéro de téléphone: 171-379-2860
- E-mail: rnair@mdanderson.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
- PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
- Availability of tumor tissue (current or archival) is required.
- Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
- ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
- Body weight 40 kg to ≤ 200 kg
- Life expectancy ≥3 months.
- Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
- Restrictions on gamete donation and freezing during and after treatment.
- Ability to provide informed consent and comply with study procedures. -
Exclusion Criteria:
- Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
- Pregnant or breastfeeding females, or those intending pregnancy.
- History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
- Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
- Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
- Use of other investigational drugs within 14 days or 5 half-lives before treatment.
- Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
- Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
- Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
- Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
- Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
- Prolonged QT/QTc interval (e.g., QTcF >480 ms).
- Active second primary malignancies except specified non-exclusionary cases.
- CNS involvement.
- Any condition that may impair compliance or study completion as judged by the Investigator.
- Known hypersensitivity to any excipients in the drug formulation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part One (Dose Escalation)
In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design. |
Intravenous infusion |
|
Expérimental: Part Two (Backfill)
Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment. |
Intravenous infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Vital signs (mmHg in Systolic/Diastolic blood pressure) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Pulse rate (beats/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Respiratory Rate (breath/min) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Temperature (°Celcius) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
ECG parameters (PR interval, QRS interval, QT interval, QTc interval) |
Through study completion, an average of 1.5 years
|
|
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Délai: Through study completion, an average of 1.5 years
|
Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD) |
Through study completion, an average of 1.5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean Blood Drug Concentration
Délai: Through study completion, an average of 1.5 years
|
The mean drug concentration in the blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the immunogenicity of KK2223.
Délai: Through study completion, an average of 1.5 years
|
Incidence of Anti drug antibodies (ADA) in blood |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years
|
% in Overall Response Rate (ORR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years
|
% in Compartment Response (if applicable) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Duration of Response (DOR) |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated |
Through study completion, an average of 1.5 years
|
|
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Délai: Through study completion, an average of 1.5 years
|
Time unit (week/month) in Time To Response (TTR) |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Délai: Through study completion, an average of 1.5 years
|
The maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Délai: Through study completion, an average of 1.5 years
|
A measure of the overall drug exposure over time |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Délai: Through study completion, an average of 1.5 years
|
The time taken to reach the maximum drug concentration |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Délai: Through study completion, an average of 1.5 years
|
The time required for the drug concentration to decrease by 50% |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Clearance (CL)
Délai: Through study completion, an average of 1.5 years
|
Rate of drug elimination from the body |
Through study completion, an average of 1.5 years
|
|
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Délai: Through study completion, an average of 1.5 years
|
Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues |
Through study completion, an average of 1.5 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome à cellules T
- Maladies hémiques et lymphatiques
- Tumeurs
- Lymphome
- Lymphome, lymphocyte T, périphérique
- Lymphome, lymphocyte T, cutané
- Maladies du système immunitaire
- Mycose fongoïde
- Syndrome de Sézary
Autres numéros d'identification d'étude
- 2223-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .